双硫死亡相关lncRNA建立胰腺癌新的预后特征并预测免疫治疗反应OACSTPCD
Disulfidptosis-related lncRNAs establish new prognostic features and predict immunotherapeutic response in pancreatic cancer
目的 筛选与双硫死亡相关的长链非编码RNA(lncRNA),研究其在胰腺癌中的免疫景观,为临床实践提供更有效的指导.方法 从癌症基因组图谱(TCGA)数据库中获取胰腺癌组织和癌旁正常组织样本,基于Cox回归和LASSO回归分析鉴定双硫死亡相关lncRNA.构建风险评分模型,通过综合方法验证其预测性能.构建精确的列线图,预测胰腺癌患者的预后.通过基因本体(GO)、基因集富集分析(GSEA)和免疫分析研究生物学差异.通过肿瘤突变负荷(TMB)估计免疫治疗反应.结果 成功鉴定出251个双硫死亡相关lncRNA,筛选出3组lncRNA作为风险评分模型的参考.通路分析结果表明,免疫相关通路与双硫死亡相关lncRNA风险评分模型相关.风险评分与免疫细胞浸润以及ESTIMATE评分显著相关.风险评分较高的患者TMB升高,表明高风险患者表现出更好的免疫检查点阻断反应.结论 本研究的发现有助于深入理解双硫死亡相关lncRNA在胰腺癌中的作用,为胰腺癌提供潜在的治疗策略.
Objective To screen long non-coding RNA(lncRNA)associated with disulfidptosis and investigate the immune landscape between lncRNA and pancreatic cancer,for effective guidance in clinical practice.Methods The normal and pancreatic cancer tissue samples were obtained from The Cancer Genome Atlas database,and the lncRNA associated with disulfidptosis was identified based on the Cox and LASSO regression analyses.A risk prognosis model was constructed,and its predictive performance was verified using comprehensive methods.An accurate nomogram was construted to predict the prognosis of patients with pancreatic cancer.The biological differences were analyzed via Gene Ontology,Gene Set Enrichment Analysis,and an immunoassay.The immunotherapy response was estimated using the tumor mutational burden(TMB)score.Results A total of 251 disulfidptosis-related lncRNAs were successfully identified,and three groups of lncRNAs were selected as the reference for the risk model.Pathway analysis showed that immune-related pathways were associated with disulfidptosis-related lncRNA risk models.The risk score was significantly correlated with immune cell infiltration and the ESTIMATE score.Patients with higher risk scores had elevated TMB,indicating that high-risk patients exhibited a better immune checkpoint blockade response.Conclusion The findings of this study contribute to a deeper understanding of disulfidpto-sis-related lncRNA and provide a potential therapeutic strategy for pancreatic cancer.
唐明政;李晓凤;荣耀;吴志航;马国榕;刘松华;蔡辉
甘肃中医药大学第一临床医学院,兰州 730000||甘肃省人民医院普外科临床医学中心,兰州 730000||甘肃省人民医院甘肃省外科肿瘤分子诊断与精准医学重点实验室,兰州 730000甘肃中医药大学第一临床医学院,兰州 730000甘肃省人民医院普外科临床医学中心,兰州 730000||甘肃省人民医院甘肃省外科肿瘤分子诊断与精准医学重点实验室,兰州 730000
临床医学
胰腺癌长链非编码RNA双硫死亡肿瘤突变负荷
pancreatic cancerlong non-coding RNAdisulfidptosistumor mutational burden
《中国医科大学学报》 2024 (001)
20-26 / 7
2021年中央引导地方科技发展基金(ZYYDDFFZZJ-1);甘肃中医药大学2023年度研究生创新创业基金
评论